Patient-centered outcomes translating clinical efficacy into benefits on health-related quality of life

Neurology

Volumn 74, Issue 17 SUPPL. 3, 2010, Pages

  Miller, Deborah ^a   Rudick, Richard A ^a   Hutchinson, Michael ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; PLACEBO;

CLINICAL ASSESSMENT; CLINICAL TRIAL; DISABILITY; DISEASE COURSE; DRUG EFFICACY; FUNCTIONAL STATUS; HUMAN; LEEDS MULTIPLE SCLEROSIS QUALITY OF LIFE SCALE; MONOTHERAPY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS IMPACT SCALE 29; MULTIPLE SCLEROSIS QUALITY OF LIFE 54; MULTIPLE SCLEROSIS QUALITY OF LIFE INVENTORY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; REMISSION; REVIEW; SHORT FORM 36; TREATMENT OUTCOME;

EID: 77951685116     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181dbb884     Document Type: Review

References (42)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000; 343: 938-952.
2. Burden of illness of multiple sclerosis: part II: quality of life. The Canadian Burden of Illness Study Group. Can J Neurol Sci 1998; 25: 31-38.
3. Interferon beta-1b is effective in relapsing-remitting multi-ple sclerosis. I. Clinical results of a multicenter, random-ized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993, 43: 655-661.
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.
5. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscu-lar interferon beta-la for disease progression in relaps-ing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
6. Randomised double-blind placebo-controlled study of in-terferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Inter-feron beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504.
7. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler 2003; 9: 63-72.
8. Miller A, Dishon S. Health-related quality of life in multi-ple sclerosis: the impact of disability, gender and employ-ment status. Qual Life Res 2006; 15: 259-271.
9. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999; 53: 1098-1103.
10. Rudick RA, Miller D, Hass S, et al; for the AFFIRM and SENTINEL Investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62: 335-346.
11. Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neu-rol Neurosurg Psychiatry 1998; 65: 460-466.
12. Thompson A, Hobart JC. Multiple sclerosis: assessment of disability and disability scales. J Neurol. 1998; 245: 189-196.
13. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
14. Jette AM, Davies AR, Cleary PD, et al. The Functional Status Questionnaire: reliability and validity when used in primary care. J Gen Intern Med 1986; 1: 143-149.
15. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sick-ness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805.
16. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-592.
17. The Consortium of Multiple Sclerosis Centers Health Ser-vices Research Subcommittee. Multiple Sclerosis Quality of Life Inventory: A User's Manual. New York: National Multiple Sclerosis Society; 1997.
18. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187-206.
19. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47: 129-139.
20. Hobart J, lamping D, Fitzpatrick R, Riazi A, Thompson A The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124(Pt 5): 962-973.
21. 21. Ford. HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001; 15: 247-258. (Pubitemid 32475720)
22. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of qual-ity of life in multiple sclerosis (MS). Mult Scler 1999; 5: 251-259.
23. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. J Neurol Neurosurg Psychiatry 2005; 76: 1539-1543.
24. McGuigan C, Hutchinson M. The multiple sclerosis im-pact scale (MSIS-29) is a reliable and sensitive measure. J Neurol Neurosurg Psychiatry 2004; 75: 266-269.
25. Costelloe L, O'Rourke K, Kearney H, et al. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry 2007; 78: 841-844.
26. Sharrack B, Hughes RA, Soudain S, Dunn G. The psycho-metric properties of clinical rating scales used in multiple sclerosis. Brain 1999; 122(Pt 1): 141-159.
27. Rudick RA, Miller D, Weinstock-Guttman B, et al. The relationship between baseline clinical measures and quality of life in patients with relapsing multiple sclerosis: analyses from the phase 3 trial of intramuscular interferon beta-1a. Mult Scler 2008; 14(suppl 1): S150. Abstract P415.
28. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of inter-feron beta-la on MSFC progression in secondary progres-sive MS. Neurology 2002; 59: 679-687.
29. Freeman JA, Thompson AJ, Fitzpatrick R, et al. Interferon-beta 1b in the treatment of secondary progres-sive MS: impact on quality of life. Neurology 2001; 57: 1870-1875.
30. Vermersch P, de Seze J, Delisse B, Le mai re S, Stojkovic T. Quality of life in multiple sclerosis: influence of interferon-beta 1a (Avonex) treatment. Mult Scler 2002; 8: 377-381.
31. Zivadinov R, Zorzon M, Tommasi MA, et al. A longitudi-nal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta 1a. J Neurol. Sci 2003; 216: 113-118.
32. Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000; 68: 144-149.
33. Rice GP, Oger J, Duquette P, et al. Treatment with inter-feron beta-lb improves quality of life in multiple sclerosis. Can J Neurol Sci 1999; 26: 276-282.
34. Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitde-haag BM, Polman CH. Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler 2000; 6: 338-342.
35. Simone IL, Ceccarelli A, Tortorella C, et al. Influence of interferon beta treatment on quality of life in multiple scle-rosis patients. Health Qual Life Outcomes [serial online] 2006; 4: 96. Available at: http://www.hqlo.com/ content/4/ 1/96. Accessed April 21, 2008.
36. Lily O, McFadden E, Hensor E, Johnson M, Ford H. Disease-specific quality of life in multiple sclerosis: the ef-fect of disease modifying treatment. Mult Scler 2006; 12: 808-813.
37. Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999; 56: 319-324.
38. Polman CH, O'Connor PW, Havrdova E, et al; for the AFFIRM Investigators. A. randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
39. Rudick RA, Stuart WH, Calabresi. PA, et al; for the SENTINEL Investigators. Natalizumab plus interferon beta-la for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
40. Miller D, Rudick DA, Calabresi PA, et al. Pain in patients with multiple sclerosis: effects of natalizumab. Presented at the 60th Annual Meeting of the American Academy of Neurology; April 12-19, 2008; Chicago.
41. National Institute of Neurological Disorders and Stroke. Neuro-QOL: Quality of Life in Neurological Disorders. Available at: http://www.neuroqol. org. Accessed Septem-ber 28, 2008.
42. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available at: http://www.fda.gov/CDER/ GUIDANCE/5460dft.pdf; 2006. Accessed October 9, 2008.